CO-VANTAGE-DATA-CENTERS
11.4.2024 12:01:30 CEST | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced that it will open a second Zurich campus (ZRH2) this summer. The highly-secure and carrier-neutral campus will provide 24MW of critical IT capacity, and when combined with Vantage’s flagship Zurich campus (ZRH1), both campuses will offer customers 64MW of capacity for their computing requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411671392/en/
Vantage Data Centers is developing 24MW ZHR2 campus located in Glattfelden just outside of Zurich, Switzerland. (Photo: Business Wire)
This campus, the company’s 33rd globally, is located 30 kilometers north of Zurich’s City Center in Glattfelden. It is conveniently situated just over 20 kilometers from Vantage’s ZRH1 campus in Winterthur and 15 minutes from Zurich Airport.
ZRH2 will have a total of 226,000 square feet (21,000 square meters) of space for Vantage’s customers consisting of hyperscalers, cloud providers and large enterprises. It comes online as the company is seeing increased demand globally to support artificial intelligence and other high-performance computing applications.
“Zurich is a rapidly growing data center market due to its strategic central location and its global financial leadership, and we expect to continue developing in this market based on customer demand,” said David Howson, president of Vantage Data Centers, EMEA. “Across Europe and the globe, the demand for highly efficient, hyperscale data centers is booming to meet the needs of next generation applications, from powerful AI models to high-performance computing and cloud transformation. Vantage is prepared to meet that demand for current and new customers, and we look forward to opening the doors of our latest data center this summer.”
Vantage Data Centers has committed to achieving net zero carbon emissions across its global portfolio by 2030 with a holistic approach to environmental sustainability. In line with the company’s “Sustainable by Design” blueprint, ZRH2 will deliver industry-leading power usage effectiveness (PUE) and water usage effectiveness (WUE) to support energy-efficient operations.
As a responsible corporate citizen who is committed to being a good neighbor, Vantage has installed air source (ASHP) and water source (WSHP) heat pumps within ZRH2. These heat pumps will convert waste heat for use to condition administrative spaces and reduce external energy use. ZRH2 will also provide waste heat to a nearby hotel and seminar center.
Additionally, ZRH2 will leverage rainwater infiltration and a green roof to minimize environmental impacts. It will feature a unique wood-finished facade, highly durable to withstand the local environment's harsh seasons and align with the look and feel of the community.
Vantage will employ more than 400 individuals during peak construction and create approximately 25 jobs to operate the campus.
To learn more about Vantage’s growing presence across EMEA, please visit: https://vantage-dc.com/data-center-locations/emea.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411671392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom